Latest Content

Among fit patients with acute myeloid leukemia, azacitidine plus Venclexta was shown to be superior to intensive chemotherapy.

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), Epkinly plus R-mini-CHOP appeared to be well tolerated and elicited responses.

Transitioning treatment with Niktimvo to a dose of 0.6 mg/kg every four weeks appeared feasible for chronic graft-versus-host disease.

Race has been identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

KRd improved progression-free survival, deepened responses, and led to higher MRD negativity versus VRd in patients with newly diagnosed multiple myeloma.

Real-time text check-ins helped physicians identify issues sooner and support quality of life for patients with myeloma at ASH 2025.

Among patients with previously untreated diffuse large B-cell lymphoma, odronextamab has been associated with early efficacy.

In patients with R/R multiple myeloma, real-world Elrexfio was associated with shorter time until progression but higher rates of response than Tecvayli.

Venclexta regimens showed comparable progression-free survival versus continuous Imbruvica.

Among children receiving chemotherapy for acute lymphoblastic leukemia, 30% of their families developed catastrophic financial toxicity.

CURE honored four individuals whose compassion and leadership shaped support education and empowerment for people living with blood cancers.

I believe time to be a gift, and as such, my sister was gifted more than a decade despite a terminal illness, and I do have gratitude for that.

Dr. Thomas Marron explains how therapeutic vaccines differ from preventative vaccines in lung cancer care.